NANOPARTICLE FORMULATION OF ROSUVASTATIN: ENHANCING SOLUBILITY AND CLINICAL POTENTIAL

Tóm tắt

Rosuvastatin is a potent statin used in the management of dyslipidemia and the prevention of
cardiovascular diseases. However, its low water solubility limits bioavailability and therapeutic
outcomes. This study outlines a nanotechnology-based method to enhance its solubility and
absorption of rosuvastatin. The process entails the formulation of rosuvastatin nanoparticles
through a combination of precipitation and ultrasonic techniques. Rosuvastatin is initially dissolved
in an organic solvent, such as acetone, and subsequently mixed with an aqueous phase containing
stabilizers like Poloxamer 407 or PVP to induce precipitation. Ultrasound reduces particle size
to 50-200 nm. Key parameters, including drug-to-stabilizer ratio, stirring speed, ultrasound
duration, and temperature, were systematically optimized to archive uniform, nanoscale particles.
The resulting nanoparticles exhibit improved stability and solubility, achieving a 6.8-fold increase
compared to unmodified Rosuvastatin. Additionally, the application of nanotechnology safeguards
the drug against gastric degradation, reduces the required dosage, and minimizes potential side
effects. This approach offers promising applications for poorly soluble drugs and significantly
improves therapeutic efficiency, marking a step forward in pharmaceutical development for better
patient outcomes